HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NOW Health Kept NAC Flag Flying, US FDA Hoists Banner For Comment On Rulemaking Request

Industry, Researcher Ask, Why Is FDA Questioning NAC Safety In Supplements?

Executive Summary

NOW Health continued marketing NAC supplements after FDA warned other firms, but some retailers opted out. FDA says rulemaking for NAC as lawful dietary ingredient is likely.

You may also be interested in...



It’s Official: US Enforcement Discretion For NAC In Supplements, And Regulatory Options For FDA

Draft guidance states enforcement discretion allowing sales of N-acetyl-L-cysteine supplements which FDA in 2020 ordered firms to halt selling due to its use as a drug ingredient. However, NAC supplements, as they have remained since 2020, were available to US consumers when draft was published.

NAC Gains Tentative Safety Clearance As US Industry Contests FDA's Attempt To Remove It

FDA answers reach supplement industry sounding like a siren that the agency may take same enforcement step it has with NAC with other ingredients long used in supplements. Answers also might not be enough to convince firms to return NAC-containing supplements to their lineups.

US FDA Put On The Clock About NAC's Use As Dietary Ingredient After Amazon Ends Sales

Trade group asked FDA six months ago to reverse position it revealed in July 2020 that products containing NAC cannot be marketed as dietary supplements. After Amazon in May reported pulling NAC supplements from its site, CRN decided to ask again.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel